Nxera Pharma (4565) Q4 2024 earnings summary

Executive summary

• Revenue surged 126% year-over-year to JPY 28.8 billion, driven by PIVLAZ® sales, full-year Pivlaz sales, and increased milestone payments from partnered programs.

• Core operating profit reached JPY 3.6 billion, reversing a prior year loss, while reported operating loss narrowed to JPY 5.4 billion as non-recurring integration and inventory costs largely ceased.

• Cash and equivalents declined to JPY 36.2 billion, mainly due to advanced API purchases for Quviviq's launch and ongoing R&D and integration investments.

• Major product launches and partnerships included QUVIVIQ™ in Japan, a global deal with Boehringer Ingelheim, and a commercial partnership with Shionogi.

• The company rebranded as Nxera Pharma, reflecting a strategic focus on innovation and APAC expansion.

Financial highlights

• Revenue: JPY 28.8 billion (+126% YoY); core operating profit: JPY 3.6 billion (vs. loss prior year); IFRS operating loss: JPY 5.4 billion (improved from JPY 9.5 billion loss YoY).

• PIVLAZ® net sales grew from JPY 6.1 billion to JPY 12.7 billion, with market share rising to ~75% among eligible patients.

• Milestone revenue increased from JPY 2.3 billion to JPY 11.2 billion, reflecting progress in partnered programs with Neurocrine, AbbVie, and Boehringer Ingelheim.

• Cash and equivalents at JPY 36.2 billion, down from JPY 49.0 billion, reflecting investment in inventory and integration.

• Non-core costs totaled JPY 9 billion, mainly from M&A, inventory adjustments, amortization, and integration costs, most of which will not recur in FY2025.

Outlook and guidance

• FY2025 guidance targets PIVLAZ® sales of JPY 13–14 billion and QUVIVIQ™ revenue of JPY 4–5 billion, with R&D expenses forecasted at JPY 12–14 billion and SG&A at JPY 15–17 billion.

• IFRS operating profit in 2025 is highly dependent on Boehringer Ingelheim exercising the GPR52 option (EUR 60 million trigger); otherwise, results may be closer to break-even.

• Long-term goal: top-line growth to over JPY 50 billion by 2029–2030, targeting 25%+ CAGR.

• No consolidated financial forecast for FY2025 due to unpredictability of milestone and partnership payments.

• Priority objectives include at least one new in-licensed late-stage asset, new partnerships, and positive IFRS operating profit if GPR52 option is exercised.